Suspension of trading

Spexis AG Share Price Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Delayed 10:06:37 19/03/2025 pm IST 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 31/03/2022
Director of Finance/CFO - 01/08/2024
Director TitleAgeSince
Chairman 70 20/11/2019
Director/Board Member 65 01/06/2013
Director/Board Member 80 30/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 8L
+3.78%+5.37%+47.06%+3.50% 8.4TCr
+2.84%+24.49%-22.44%-35.85% 5.68TCr
+0.85%-0.32%-1.93%+30.25% 5.14TCr
+0.62%+0.09%+12.35%+169.08% 4.84TCr
+4.24%+6.08%+59.56%-15.16% 3.27TCr
+176.97%+173.88%+524.79%+71.60% 6.96TCr
+4.05%+6.38%+50.33%+100.61% 2.6TCr
+3.00%+6.36%+6.92%+224.88% 2.18TCr
-0.56%+3.30%+63.05%+125.83% 1.71TCr
Average +1.69%+24.15%+65.08%+57.55% 4.53TCr
Weighted average by Cap. +1.47%+34.60%+108.39%+54.35%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B